

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 480140.442C1		APPLICATION NO. 09/765,105	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS Donald S. Karanewsky et al.			
				FILING DATE January 16, 2001		GROUP ART UNIT 1653	
<b>U.S. PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	6,235,899	05/22/01	Bouchet et al.	540	500	
	AB						
	AC						
	AD						
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO		
	AE	WO 97/22619	06/26/97	WIPO			
	AF	WO 98/10778	03/19/98	WIPO			
	AG	WO 99/03852	01/28/99	WIPO (+ English Translation)		X	
	AH	WO 00/01666	01/13/00	WIPO			
	AI	WO 00/23421	04/27/00	WIPO			
	AJ	WO 01/00658	01/04/01	WIPO			
	AK	WO 01/51462	07/19/01	WIPO			
	AL	WO 01/81330	11/01/01	WIPO			
<b>OTHER PRIOR ART</b> (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AM	Chapman K., "Synthesis of a Potent, Reversible Inhibitor of Interleukin-1 $\beta$ Converting Enzyme," <i>Bioorganic &amp; Medicinal Chemistry Letters</i> 2(6):613-618, 1992.					
	AN	Cheung et al., "Synthesis of 3-Amino-3-Vinylpropanoic Acid and its Conversion to 4-Amino-5-Hydroxy-4,5-Dihydrofuran-2-one Hydrochloride (HAD), A Cyclic Stabilised Form of Aspartate 1-Semialdehyde Hydrochloride," <i>Tetrahedron</i> 53(46):15807-15812, 1997.					
	AO	de Lange et al., "Asymmetric 1, 4-Additions to 5-Alkoxy-2(5H)-Furanones Enantioselective Synthesis and Absolute Configuration Determination of $\beta$ -Amino- $\gamma$ -Butyrolactones and Amino Diols," <i>Tetrahedron</i> 45(21):6799-6818, 1989.					
EXAMINER 				DATE CONSIDERED 02-05-04			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-1449  
(REV.7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
480140.442C1APPLICATION NO.  
09/765,105INFORMATION DISCLOSURE STATEMENT  
(Use several sheets if necessary)

## APPLICANTS

Donald S. Karanewsky et al.

## FILING DATE

January 16, 2001

## GROUP ART UNIT

1653

## U.S. PATENT DOCUMENTS

INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA					
	BB					
	BC					
	BD					

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
	BE				
	BF				
	BG				

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

DL	BH	Faber et al., "Catalytic Kinetic Resolution of 5-Alkoxy-2(5H)-Furanones," <i>Tetrahedron</i> 50(16):4775-4794, 1994.
	BI	Feringa et al., "Asymmetric Synthesis of 2-Amino-1, 4-Diols," <i>Tetrahedron Letters</i> 29(11):1303-1306, 1988.
	BJ	Feringa et al., "1, 4-Additions of Amines to 5-Methoxyfuran-2(5H)-One; An Efficient Synthesis of Amino Diols," <i>Heterocycles</i> 27(5):1197-1205, 1988.
	BK	Furuichi et al., "Common Synthetic Strategy for Optically Active Cyclic Terpenoids having a 1,1,5-Trimethyl- <i>Trans</i> -Decalin Nucleus: Syntheses of (+)-Acuminolide, (-)-Spongianolide A, and (+)-Scalareneal," <i>Tetrahedron</i> 57, pp. 8425-8442, 2001.
	BL	Gonzalez et al., "Pseudoesters and Derivatives. Part38. 1,3-Dipolar Cycloadditions of Aryl Azides and an Aziridine, Via Azomethine Ylide, to 2(5H)-Furanones Substituted at the 5-Position by Methoxy and Sulfur Bearing Groups," <i>Heterocycles</i> 52(1):237-251, 2000.
	BM	Leblanc et al., "Sar in the Alkoxy Lactone Series: The Discovery of DFP, A Potent and Orally Active Cox-2 Inhibitor," <i>Bioorganic &amp; Medicinal Chemistry Letters</i> 9, pp. 2207-2212, 1999.
DL	BN	Lubben et al., "Asymmetric Synthesis of $\beta$ -Lactams via Amine Additions to 5(R)-Menthylloxy-2(5H)-Furanone," <i>Tetrahedron: Asymmetry</i> 2(8):775-778, 1991.

EXAMINER

David L. L. L.

DATE CONSIDERED

02-04-09

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).